[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vegfr-tki\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vegfr-tki":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100602541",false,"NCT07124858","Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","PRODIGE 108 - COHORTE 2320 - COFRUQ Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","COFRUQ","Inclusion Criteria:\n\n* Patients aged 18 and over.\n* Histologically confirmed colorectal adenocarcinoma with locally advanced disease and\u002For unresectable metastasis(es) receiving treatment with fruquintinib under i) compassionate\u002Fearly access and ii) marketing authorisation and reimbursement in France.\n* Obtain informed consent from the patient for the clinical-biological cohort.\n* Agreement to take biological samples of ctDNA and send tumour blocks (patient participation in the pharmacokinetic study remains optional).\n\nExclusion Criteria:\n\n* Patient with another concurrent cancer at the time of diagnosis, requiring systemic treatment or influencing prognosis (in the opinion of the centre's medical team).\n* Contraindication due to psychological or social reasons that may hinder follow-up (cognitive deficit, psychological disorders incompatible with obtaining consent; inability to be followed in the same centre throughout the follow-up period for geographical reasons).\n* Pregnant or breast-feeding women.\n* Patients under court protection or subject to a protective measure (patient under guardianship or curatorship).","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.",[26,27,28],"Metastatic Colorectal Cancer (CRC)","Antineoplastic Agents, Immunological","VEGFR-TKI",[30,31,32],"Metastatic colorectal cancer","Fruquintinib","cohort","RECRUITING","2026-05-22",{"date":36,"type":37},"2026-05-26","ACTUAL",{"date":39,"type":37},"2026-03-10",{"date":41,"type":20},"2031-12-31",{"name":43,"class":44},"Federation Francophone de Cancerologie Digestive","OTHER",83,""]